Company registration number 10984711 (England and Wales)
3CR BIOSCIENCE LIMITED
UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 SEPTEMBER 2024
3CR BIOSCIENCE LIMITED
CONTENTS
Page
Balance sheet
1 - 2
Notes to the financial statements
3 - 6
3CR BIOSCIENCE LIMITED
BALANCE SHEET
AS AT
30 SEPTEMBER 2024
30 September 2024
- 1 -
2024
2023
Notes
£
£
£
£
Fixed assets
Tangible assets
3
190,289
143,673
Current assets
Stocks
143,590
143,838
Debtors
4
400,964
235,150
Investments
5
105,169
93,035
Cash at bank and in hand
1,291,001
740,624
1,940,724
1,212,647
Creditors: amounts falling due within one year
6
(184,711)
(100,821)
Net current assets
1,756,013
1,111,826
Total assets less current liabilities
1,946,302
1,255,499
Provisions for liabilities
(47,572)
(35,918)
Net assets
1,898,730
1,219,581
Capital and reserves
Called up share capital
300
300
Fair value reserve
7
2,140
(9,136)
Profit and loss reserves
1,896,290
1,228,417
Total equity
1,898,730
1,219,581

The directors of the company have elected not to include a copy of the profit and loss account within the financial statements.true

For the financial year ended 30 September 2024 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

3CR BIOSCIENCE LIMITED
BALANCE SHEET (CONTINUED)
AS AT
30 SEPTEMBER 2024
30 September 2024
- 2 -
The financial statements were approved by the board of directors and authorised for issue on 13 June 2025 and are signed on its behalf by:
Mr S R Asquith
Director
Company Registration No. 10984711
3CR BIOSCIENCE LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 SEPTEMBER 2024
- 3 -
1
Accounting policies
Company information

3CR BIOSCIENCE LIMITED is a private company limited by shares incorporated in England and Wales. The registered office is Unit 10, West Point Business Park, West Road, Harlow, Essex, CM20 2BU.

1.1
Accounting convention

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.

1.2
Turnover

Turnover is measured at the fair value of the consideration received or receivablee, excluding discounts, rebates, value added tax and other sales taxes.

1.3
Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Leasehold improvements
Over the term of the lease
Plant and equipment
20% on cost
Fixtures and fittings
20% on cost
Computers
33% on cost

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.

1.4
Stocks

Stocks are valued at the lower of cost and net realisable value, after making due allowances for obsolete and slow moving items.

1.5
Taxation

The tax expense represents the sum of the tax currently payable and deferred tax.

Current tax

The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the profit and loss account because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The company’s liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the reporting end date.

3CR BIOSCIENCE LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 SEPTEMBER 2024
1
Accounting policies
(Continued)
- 4 -
Deferred tax

Deferred tax liabilities are generally recognised for all timing differences and deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Such assets and liabilities are not recognised if the timing difference arises from goodwill or from the initial recognition of other assets and liabilities in a transaction that affects neither the tax profit nor the accounting profit.

 

The carrying amount of deferred tax assets is reviewed at each reporting end date and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered. Deferred tax is calculated at the tax rates that are expected to apply in the period when the liability is settled or the asset is realised. Deferred tax is charged or credited in the profit and loss account, except when it relates to items charged or credited directly to equity, in which case the deferred tax is also dealt with in equity. Deferred tax assets and liabilities are offset when the company has a legally enforceable right to offset current tax assets and liabilities and the deferred tax assets and liabilities relate to taxes levied by the same tax authority.

1.6
Retirement benefits

Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.

1.7
Leases

Rentals payable under operating leases, including any lease incentives received, are charged to profit or loss on a straight line basis over the term of the relevant lease except where another more systematic basis is more representative of the time pattern in which economic benefits from the leases asset are consumed.

1.8
Foreign exchange

Transactions in currencies other than pounds sterling are recorded at the rates of exchange prevailing at the dates of the transactions. At each reporting end date, monetary assets and liabilities that are denominated in foreign currencies are retranslated at the rates prevailing on the reporting end date. Gains and losses arising on translation in the period are included in profit or loss.

1.9

Current asset investments

Current asset investments are initially measured at transaction price excluding transaction costs, and are subsequently measured at fair value at each reporting date. Changes in fair value are recognised in profit or loss. Transaction costs are expensed to profit or loss as incurred.

2
Employees

The average monthly number of persons (including directors) employed by the company during the year was:

2024
2023
Number
Number
Total
10
9
3CR BIOSCIENCE LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 SEPTEMBER 2024
- 5 -
3
Tangible fixed assets
Leasehold improvements
Plant and equipment
Fixtures and fittings
Computers
Total
£
£
£
£
£
Cost
At 1 October 2023
62,398
172,054
16,276
34,448
285,176
Additions
84,440
14,647
26,270
7,193
132,550
At 30 September 2024
146,838
186,701
42,546
41,641
417,726
Depreciation and impairment
At 1 October 2023
29,338
78,205
12,031
21,929
141,503
Depreciation charged in the year
27,785
45,688
4,959
7,502
85,934
At 30 September 2024
57,123
123,893
16,990
29,431
227,437
Carrying amount
At 30 September 2024
89,715
62,808
25,556
12,210
190,289
At 30 September 2023
33,060
93,849
4,245
12,519
143,673
4
Debtors
2024
2023
Amounts falling due within one year:
£
£
Trade debtors
347,193
199,638
Amounts owed by group undertakings
10,300
-
0
Other debtors
43,471
35,512
400,964
235,150
5
Current asset investments
2024
2023
£
£
Other investments
105,169
93,035
3CR BIOSCIENCE LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 SEPTEMBER 2024
- 6 -
6
Creditors: amounts falling due within one year
2024
2023
£
£
Trade creditors
26,868
36,189
Taxation and social security
150,888
60,507
Other creditors
6,955
4,125
184,711
100,821
7
Fair value reserve
2024
2023
£
£
At the beginning of the year
(9,136)
(17,143)
Transfer to retained earnings
11,276
8,007
At the end of the year
2,140
(9,136)
8
Operating lease commitments
Lessee

At the reporting end date the company had outstanding commitments for future minimum lease payments under non-cancellable operating leases, as follows:

2024
2023
£
£
57,396
202,396
2024-09-302023-10-01falsefalsefalse13 June 2025CCH SoftwareCCH Accounts Production 2025.100No description of principal activityDr J E HolmeMrs N JainMr S R AsquithMr S JainMiss W BottenDr S E HolmeMr S R Asquith109847112023-10-012024-09-30109847112024-09-30109847112023-09-3010984711core:LeaseholdImprovements2024-09-3010984711core:PlantMachinery2024-09-3010984711core:FurnitureFittings2024-09-3010984711core:ComputerEquipment2024-09-3010984711core:LeaseholdImprovements2023-09-3010984711core:PlantMachinery2023-09-3010984711core:FurnitureFittings2023-09-3010984711core:ComputerEquipment2023-09-3010984711core:CurrentFinancialInstrumentscore:WithinOneYear2024-09-3010984711core:CurrentFinancialInstrumentscore:WithinOneYear2023-09-3010984711core:CurrentFinancialInstruments2024-09-3010984711core:CurrentFinancialInstruments2023-09-3010984711core:ShareCapital2024-09-3010984711core:ShareCapital2023-09-3010984711core:RevaluationReserve2024-09-3010984711core:RevaluationReserve2023-09-3010984711core:RetainedEarningsAccumulatedLosses2024-09-3010984711core:RetainedEarningsAccumulatedLosses2023-09-3010984711core:RevaluationReserve2023-09-3010984711core:RevaluationReserve2022-09-3010984711bus:CompanySecretaryDirector12023-10-012024-09-3010984711core:LeaseholdImprovements2023-10-012024-09-3010984711core:PlantMachinery2023-10-012024-09-3010984711core:FurnitureFittings2023-10-012024-09-3010984711core:ComputerEquipment2023-10-012024-09-30109847112022-10-012023-09-3010984711core:LeaseholdImprovements2023-09-3010984711core:PlantMachinery2023-09-3010984711core:FurnitureFittings2023-09-3010984711core:ComputerEquipment2023-09-30109847112023-09-3010984711core:WithinOneYear2024-09-3010984711core:WithinOneYear2023-09-3010984711core:RevaluationReserve2023-10-012024-09-3010984711core:RevaluationReserve2022-10-012023-09-3010984711bus:PrivateLimitedCompanyLtd2023-10-012024-09-3010984711bus:SmallCompaniesRegimeForAccounts2023-10-012024-09-3010984711bus:FRS1022023-10-012024-09-3010984711bus:AuditExemptWithAccountantsReport2023-10-012024-09-3010984711bus:Director12023-10-012024-09-3010984711bus:Director22023-10-012024-09-3010984711bus:Director32023-10-012024-09-3010984711bus:Director42023-10-012024-09-3010984711bus:Director52023-10-012024-09-3010984711bus:Director62023-10-012024-09-3010984711bus:CompanySecretary12023-10-012024-09-3010984711bus:FullAccounts2023-10-012024-09-30xbrli:purexbrli:sharesiso4217:GBP